These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3144739)

  • 1. Fibrinolysis and atherosclerosis.
    Collen D; Juhan-Vague I
    Semin Thromb Hemost; 1988 Apr; 14(2):180-3. PubMed ID: 3144739
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lipoprotein-mediated functional changes in the fibrinolytic system in the genesis of atherosclerosis].
    García Frade LJ; García Avello A
    Sangre (Barc); 1991 Feb; 36(1):25-8. PubMed ID: 1649496
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue.
    Juhan-Vague I; Alessi MC
    Thromb Haemost; 1999 Aug; 82(2):832-6. PubMed ID: 10605790
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrinolytic system in atherosclerosis.
    Balkuv-Ulutin S
    Semin Thromb Hemost; 1986 Apr; 12(2):91-101. PubMed ID: 3738530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
    Gurewich V
    Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis.
    Jones AJ; Meunier AM
    Thromb Haemost; 1990 Nov; 64(3):455-63. PubMed ID: 2128976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrinolytic system and hyperinsulinism].
    Juhan-Vague I
    Journ Annu Diabetol Hotel Dieu; 1990; ():181-91. PubMed ID: 2114499
    [No Abstract]   [Full Text] [Related]  

  • 9. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans.
    Oliver JJ; Webb DJ; Newby DE
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2470-9. PubMed ID: 16210566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of fibrinolysis laboratory tests: a review.
    Prisco D; Conti AA; Giurlani L; Falciani M
    Ann Ital Med Int; 1998; 13(2):81-7. PubMed ID: 9734140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples.
    Lewis MR; Callas PW; Jenny NS; Tracy RP
    Thromb Haemost; 2001 Dec; 86(6):1495-500. PubMed ID: 11776319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis.
    Pizzo SV; Fuchs HE; Doman KA; Petruska DB; Berger H
    Arch Intern Med; 1986 Jan; 146(1):188-91. PubMed ID: 2935105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relations between fibrinolysis and human atherosclerosis. Tissue activator of plasminogen of the arterial wall].
    Tesi M; Caramelli L
    Boll Soc Ital Cardiol; 1973; 18(2):181-94. PubMed ID: 4807057
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
    J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion.
    Schoots IG; Levi M; van Vliet AK; Declerck PJ; Maas AM; van Gulik TM
    Thromb Haemost; 2004 Mar; 91(3):497-505. PubMed ID: 14983225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal but not hypertriglyceridemic very low-density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells.
    Booyse FM; Bruce R; Gianturco SH; Bradley WA
    Semin Thromb Hemost; 1988 Apr; 14(2):175-9. PubMed ID: 3144738
    [No Abstract]   [Full Text] [Related]  

  • 18. [Importance of the structure of the clot in thrombolysis].
    Soria C; Soria J; Mirshahi M; Desvignes P; Bonnet P; Caen JP
    Ann Biol Clin (Paris); 1987; 45(2):207-11. PubMed ID: 2441630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of tissue type plasminogen activator in the glomeruli of patients with IgA nephropathy.
    Garcia G; Miura M; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1989 Apr; 14(2):131-7. PubMed ID: 2517871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
    Carr ME; Krishnamurti C; Alving BM
    Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.